{"filing":{"accession_number":"0001213900-26-063481","cik":"0000907654","ticker":"ORKA","company_name":"Oruka Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"ea0292876-8k_oruka.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/ea0292876-8k_oruka.htm"},"events":[{"id":7857,"run_id":6894,"accession_number":"0001213900-26-063481","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Oruka entered into a First Amendment to its IL-23 License Agreement with Paragon Therapeutics on May 29, 2026, expanding the Field to include inflammatory bowel disease—a significant therapeutic expansion for the Company's lead candidate ORKA-001. While this is a material licensing amendment affecting the Company's development rights and commercial scope, it does not fit cleanly into the more specific event categories (not an M\u0026A transaction, not a covenant breach, not a restatement or going-concern issue). The expansion of therapeutic indications and the conditional restrictions on dosing timelines represent a material modification to the Company's intellectual property and development strategy.","company_name":"Oruka Therapeutics, Inc.","ticker":"ORKA","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3232,"accession_number":"0001213900-26-063481","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Oruka entered into a First Amendment to its IL-23 License Agreement with Paragon Therapeutics on May 29, 2026, expanding the Field to include inflammatory bowel disease—a significant therapeutic expansion for the Company's lead candidate ORKA-001. While this is a material licensing amendment affecting the Company's development rights and commercial scope, it does not fit cleanly into the more specific event categories (not an M\u0026A transaction, not a covenant breach, not a restatement or going-concern issue). The expansion of therapeutic indications and the conditional restrictions on dosing timelines represent a material modification to the Company's intellectual property and development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:45:11.866988+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3232,"accession_number":"0001213900-26-063481","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Oruka entered into a First Amendment to its IL-23 License Agreement with Paragon Therapeutics on May 29, 2026, expanding the Field to include inflammatory bowel disease—a significant therapeutic expansion for the Company's lead candidate ORKA-001. While this is a material licensing amendment affecting the Company's development rights and commercial scope, it does not fit cleanly into the more specific event categories (not an M\u0026A transaction, not a covenant breach, not a restatement or going-concern issue). The expansion of therapeutic indications and the conditional restrictions on dosing timelines represent a material modification to the Company's intellectual property and development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:45:11.866988+00:00","company_name":"Oruka Therapeutics, Inc.","ticker":"ORKA","filing_date":"2026-06-01"}]}